Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Pramipexole ER vs. Placebo in Fibromyalgia

ClinicalTrials.gov ID: NCT00689052

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00689052. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Dose Titration Efficacy and Safety Study of Pramipexole ER (0.75 to 4.5 mg) Administered Orally Once Daily Versus Placebo Over a 16-week Maintenance Phase in Patients Diagnosed With Fibromyalgia, as Assessed by the American College of Rheumatology (ACR) Criteria Followed by a 24-week Open-label Extension Phase

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to assess the efficacy and safety of an extended-release (ER) formulation of pramipexole in comparison with placebo for the treatment of fibromyalgia. The objective of the open-label phase is to assess the safety profile and effect of Pramipexole (PPX) extended-release (ER) in fibromyalgia patients over a 24-week period.

Study identification

NCT ID
NCT00689052
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
61 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 2008 (Type not available)
Primary completion
Nov 2008 (Actual)
Completion
Not listed
Last update posted
Jun 9, 2014

Started 2008

United States locations

U.S. sites
42
U.S. states
27
U.S. cities
42
Facility City State ZIP Site status
248.637.01009 Boehringer Ingelheim Investigational Site Birmingham Alabama — —
248.637.01033 Boehringer Ingelheim Investigational Site Phoenix Arizona — —
248.637.01045 Boehringer Ingelheim Investigational Site Tucson Arizona — —
248.637.01034 Boehringer Ingelheim Investigational Site Hot Springs Arkansas — —
248.637.01032 Boehringer Ingelheim Investigational Site Arcadia California — —
248.637.01044 Boehringer Ingelheim Investigational Site Los Angeles California — —
248.637.01036 Boehringer Ingelheim Investigational Site Santa Ana California — —
248.637.01042 Boehringer Ingelheim Investigational Site Englewood Colorado — —
248.637.01031 Boehringer Ingelheim Investigational Site Danbury Connecticut — —
248.637.01035 Boehringer Ingelheim Investigational Site DeLand Florida — —
248.637.01023 Boehringer Ingelheim Investigational Site Fort Myers Florida — —
248.637.01047 Boehringer Ingelheim Investigational Site Orlando Florida — —
248.637.01043 Boehringer Ingelheim Investigational Site Palm Beach Gardens Florida — —
248.637.01040 Boehringer Ingelheim Investigational Site Sunrise Florida — —
248.637.01027 Boehringer Ingelheim Investigational Site Tampa Florida — —
248.637.01007 Boehringer Ingelheim Investigational Site Atlanta Georgia — —
248.637.01028 Boehringer Ingelheim Investigational Site Chicago Illinois — —
248.637.01010 Boehringer Ingelheim Investigational Site Lexington Kentucky — —
248.637.01016 Boehringer Ingelheim Investigational Site Newton Massachusetts — —
248.637.01014 Boehringer Ingelheim Investigational Site Lansing Michigan — —
248.637.01020 Boehringer Ingelheim Investigational Site Flowood Mississippi — —
248.637.01018 Boehringer Ingelheim Investigational Site Picayune Mississippi — —
248.637.01012 Boehringer Ingelheim Investigational Site Kansas City Missouri — —
248.637.01017 Boehringer Ingelheim Investigational Site Billings Montana — —
248.637.01024 Boehringer Ingelheim Investigational Site Albuquerque New Mexico — —
248.637.01008 Boehringer Ingelheim Investigational Site Albany New York — —
248.637.01002 Boehringer Ingelheim Investigational Site New York New York — —
248.637.01025 Boehringer Ingelheim Investigational Site Charlotte North Carolina — —
248.637.01026 Boehringer Ingelheim Investigational Site Fargo North Dakota — —
248.637.01004 Boehringer Ingelheim Investigational Site Cincinnati Ohio — —
248.637.01038 Boehringer Ingelheim Investigational Site Columbus Ohio — —
248.637.01003 Boehringer Ingelheim Investigational Site Oklahoma City Oklahoma — —
248.637.01046 Boehringer Ingelheim Investigational Site Medford Oregon — —
248.637.01006 Boehringer Ingelheim Investigational Site Portland Oregon — —
248.637.01039 Boehringer Ingelheim Investigational Site Duncansville Pennsylvania — —
248.637.01015 Boehringer Ingelheim Investigational Site Warwick Rhode Island — —
248.637.01019 Boehringer Ingelheim Investigational Site Austin Texas — —
248.637.01037 Boehringer Ingelheim Investigational Site San Antonio Texas — —
248.637.01041 Boehringer Ingelheim Investigational Site Salt Lake City Utah — —
248.637.01021 Boehringer Ingelheim Investigational Site Renton Washington — —
248.637.01029 Boehringer Ingelheim Investigational Site Seattle Washington — —
248.637.01011 Boehringer Ingelheim Investigational Site Spokane Washington — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00689052, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 9, 2014 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.